CD33 and B-cell non-Hodgkin lymphoma: Loncastuximab tesirine targeting CD19 for the treatment of B cell lymphomas has been approved in 2021 [135]. However, vadastuximab talirine targeting CD33 and rovalpituzumab tesirine targeting DLL3 were discontinued following pivotal studies.